Lanifibranor
As of the edition of 20 October 2026, Lanifibranor is a small molecule: in active development; acts on PPARA, PPARD and PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Digestive system; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Inventiva Pharma | Lead sponsor of trials | 2017 to now |
| Chia Tai Tianqing Pharmaceutical | Lead sponsor of trials | 2023 to now |